Infosys to acquire life science consulting and technology leader BASE life science
Acquisition to deepen life science domain capabilities and strengthen footprint across Europe
BENGALERU, India and Copenhagen, Denmark, July 13, 2022 /PRNewswire/ — Infosys (NSE, BSE,NYSE:INFY), a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire BASIC life sciencesa leading technology and consulting company in the life sciences industry, Europe. The acquisition reaffirms our commitment to helping global life sciences companies realize commercial value from cloud-first digital platforms and data, accelerate clinical trials and scale drug development, by positively impacting lives and achieving better health outcomes.
BASE brings to Infosys domain experts with business, medical, digital marketing, clinical, regulatory and quality know-how. Supported by a team of data science specialists, BASE is at the frontier of the latest technological developments and trends. It has a strong focus on data and AI, and the ability to link and integrate business logic and technology, which generates insights for better health outcomes.
Based at Denmark, BASE is one of the fastest growing technology and consulting partners in the life science industry. The company has approximately 200 of the industry’s top multidisciplinary experts across Denmark, SwissUK, Germany, France, Italyand a nearshore technology hub in Spain. Together with Infosys, BASE will further expand its portfolio of expertise in the Consumer Health, Animal Health, MedTech and Genomics segments. BASE works with leading life sciences software technology providers such as Veeva, IQVIA and Salesforce.
Ravi Kumar S, President, Infosyssaid, “This acquisition strengthens Infosys’ deep expertise in life sciences and further expands our footprint in the Nordic region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions. We are delighted to welcome BASE life science and its management team to the Infosys family. »
“Over the past five years, BASE life science has experienced phenomenal growth and created a leading life science consulting company in Europe. With Infosys as a catalyst, we will be able to accelerate our international expansion and create development opportunities for our employees. Infosys is a strong global technology leader that is uniquely suited to ensure BASE’s continued success while sharing our common purpose and values.” Martin Woergaard, CEO, BASE life sciences.
The acquisition is expected to close in the second quarter of fiscal 2023, subject to customary closing conditions.
VEEVA is a trademark of Veeva Systems Inc.
IQVIA is a trademark of IQVIA Holdings Inc.
Salesforce is a trademark of salesforce.com, inc.
About BASE life sciences A/S
BASE life science is an innovative and forward-thinking technology, product and services consultancy specializing in creating real business value from digital platforms and data, growing people and delivering innovative solutions that make an impact. durable and sustainable in an industry that matters.
Its experienced teams optimize technology and business processes in the areas of customer engagement, quality, regulatory, compliance and clinical data management for life sciences companies.
BASE life science’s aspiration is to be the leading life science technology consulting firm in Europe and currently operates from offices located in Denmark, Swiss, Spain, Italy, France, UK and Germany from where they help customers around the world. Fueled by the hard work and efforts of its dedicated teams, BASE life science has established itself as a trusted advisor to the life science industry, striving for continuous excellence to remain a trusted partner able to successfully realize the visions of its clients. www.baselifescience.com
Infosys is a global leader in next-generation digital services and consulting. More than 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. With over four decades of experience managing the systems and operations of global enterprises, we expertly guide clients, in over 50 countries, as they navigate their cloud-powered digital transformation. We empower them with an AI-powered core, equip the business with agile digital at scale, and drive continuous improvement with continuous learning through the transfer of digital skills, expertise, and ideas from our ecosystem. of innovation. We are deeply committed to being a well-governed, environmentally responsible organization where diverse talent thrives in an inclusive workplace.
Visit infosys.com to see how Infosys (NSE, BSE, NYSE:INFY) can help your business navigate your next.
Certain statements in this release regarding our future growth prospects, financial expectations and plans to manage the impact of COVID-19 on our employees, customers and stakeholders are forward-looking statements intended to qualify for the “sphere Security” under the Private Securities Litigation Reform Act. 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those contained in such forward-looking statements. The risks and uncertainties associated with these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of governmental and other measures to contain its spread, risks relating to an economic downturn or recession in India, United States and other countries around the world, changes in political, business and economic conditions, fluctuations in earnings, fluctuations in currency exchange rates, our ability to manage growth, intense competition in IT services, including factors that could to affect our cost advantage, salary increases in India and in the United States, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price and fixed-term contracts, customer concentration, immigration restrictions, concentration of industry segments, our ability to manage our international operations, reduced demand for technology in our core focus areas, telecommunications network disruptions or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of businesses in which Infosys has made strategic investments, the withdrawal or expiration of government tax incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring businesses outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigations. Additional risks that could affect our future results of operations are further described in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended March 31, 2022. These files are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company, except as required by law.
For more information please contact: [email protected]